Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.
← Back to Medmonitor

Medication Type: Seizures

Briviact (brivaracetam) tablets

Approval Date: Jun 2022

Note: First-Time Generic

Indicated for the treatment of partial-onset seizures.

Zonisade (zonisamide) oral suspension

Approval Date: Jul 2022

Note: New Dosage or Formulation

Indicated as an adjunctive therapy for the treatment of partial-onset seizures, this approval is for the first liquid formulation of zonisamide.

Vimpat (lacosamide) tablets

Approval Date: Mar 2022

Note: First-Time Generic

A first-time generic for Vimpat, this drug treats partial onset seizures

Aptiom® (eslicarbazepine acetate) tablets

Approval Date: Jun 2021

Note: First-Time Generic

This is the first time a generic has been approved for Aptiom. For the adjunctive treatment of partial-onset seizures

Medication Name

Approval Date

Category

Description

Briviact (brivaracetam) tablets

Jun 2022

Indicated for the treatment of partial-onset seizures.

Note: First-Time Generic

Zonisade (zonisamide) oral suspension

Jul 2022

Indicated as an adjunctive therapy for the treatment of partial-onset seizures, this approval is for the first liquid formulation of zonisamide.

Note: New Dosage or Formulation

Vimpat (lacosamide) tablets

Mar 2022

A first-time generic for Vimpat, this drug treats partial onset seizures

Note: First-Time Generic

Aptiom® (eslicarbazepine acetate) tablets

Jun 2021

This is the first time a generic has been approved for Aptiom. For the adjunctive treatment of partial-onset seizures

Note: First-Time Generic
lockenvelopephone-handsetmenucross-circle